Pamela Stephenson net worth and biography

Pamela Stephenson Biography and Net Worth

Insider of Disc Medicine

Pamela has more than 20 years of biopharma commercial leadership experience across multiple functions and disease areas. She most recently served as Chief Commercial Officer at Albireo Pharma. Before joining Albireo, she served as Vice President, Global Market Access and Value, at Vertex Pharmaceuticals, where she led the global market access and pricing strategy for current and future products. Earlier in her tenure at Vertex, she led marketing and sales activities for the company’s hepatitis C and cystic fibrosis lines of business, and oversaw the U.S. launches of Incivek® (telaprevir) and Orkambi®(lumacaftor/ivacaftor). Prior to Vertex, Pamela spent 10 years at Pfizer in marketing roles of increasing responsibility for brands such as Viagra® (sildenafil citrate), Lyrica® (pregabalin), and Aromasin® (exemestane). Pamela holds a bachelor’s degree from Brown University and received her master’s degree in public health from Boston University School of Public Health.

What is Pamela Stephenson's net worth?: The estimated net worth of Pamela Stephenson is at least $3.64 million as of February 18th, 2025. Stephenson owns 69,529 shares of Disc Medicine stock worth more than $3,644,015 as of March 14th. This net worth estimate does not reflect any other investments that Stephenson may own. Learn More about Pamela Stephenson's net worth.
How old is Pamela Stephenson?: Stephenson is currently 56 years old. There are 7 older executives and no younger executives at Disc Medicine. The oldest executive at Disc Medicine is Dr. Donald William Nicholson Ph.D., Executive Chairman, who is 66 years old. Learn More on Pamela Stephenson's age.
How do I contact Pamela Stephenson?: The corporate mailing address for Stephenson and other Disc Medicine executives is 297 Boston Post Road #248, Wayland MA, 01778. Disc Medicine can also be reached via phone at 617-401-4400 and via email at ir@geminitherapeutics.com. Learn More on Pamela Stephenson's contact information.
Has Pamela Stephenson been buying or selling shares of Disc Medicine?: During the last quarter, Pamela Stephenson has sold $171,217.46 of Disc Medicine stock. Most recently, Pamela Stephenson sold 3,137 shares of the business's stock in a transaction on Tuesday, February 18th. The shares were sold at an average price of $54.58, for a transaction totalling $171,217.46. Following the completion of the sale, the insider now directly owns 69,529 shares of the company's stock, valued at $3,794,892.82. Learn More on Pamela Stephenson's trading history.
Who are Disc Medicine's active insiders?: Disc Medicine's insider roster includes Mona Ashiya (Director), Kevin Bitterman (Director), Joanne Bryce (CFO), Jean Franchi (CFO), Rahul Khara (Insider), Brian Macdonald (Insider), John Quisel (CEO), William Savage (Insider), Pamela Stephenson (Insider), William White (Director), and Jonathan Yu (COO). Learn More on Disc Medicine's active insiders.
Are insiders buying or selling shares of Disc Medicine?: During the last year, insiders at the sold shares 19 times. They sold a total of 395,005 shares worth more than $22,156,241.87. The most recent insider tranaction occured on March, 12th when Director Mona Ashiya sold 83,182 shares worth more than $4,529,259.90. Insiders at Disc Medicine own 4.2% of the company. Learn More about insider trades at Disc Medicine.
Information on this page was last updated on 3/12/2025.

Pamela Stephenson Insider Trading History at Disc Medicine

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
2/18/2025	Sell	3,137	$54.58	$171,217.46	69,529

Pamela Stephenson Buying and Selling Activity at Disc Medicine

Disc Medicine Company Overview

Disc Medicine, Inc., together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis. Its pipeline includes bitopertin for the treatment of erythropoietic porphyrias, including erythropoietic protoporphyria, X-linked protoporphyria, and diamond-blackfan anemia; DISC-0974 for the treatment of anemia of myelofibrosis, and anemia of chronic kidney disease; and DISC-3405 for the treatment of polycythemia vera, and other hematologic disorders. The company's preclinical programs include DISC-0998, for the treatment of anemia associated with inflammatory diseases. Disc Medicine, Inc. was founded in 2017 and is headquartered in Watertown, Massachusetts.

Today's Range

Now: $52.41

$52.36

$54.84

50 Day Range

MA: $56.62

$53.37

$63.82

2 Week Range

Now: $52.41

$25.60

$68.86

Volume

263,058 shs

Average Volume

359,832 shs

Market Capitalization

$1.81 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.73

Pamela Stephenson Biography and Net Worth

What is Pamela Stephenson's net worth?

How old is Pamela Stephenson?

How do I contact Pamela Stephenson?

Has Pamela Stephenson been buying or selling shares of Disc Medicine?

Who are Disc Medicine's active insiders?

Are insiders buying or selling shares of Disc Medicine?